BackHumacyte Overview
Humacyte Inc

Humacyte Target Price

See Humacyte's analyst price targets ($1.5) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$0.44

Average Target Price

$1.50244.5% upside

2 analysts in the last 4 months

High: $2 | Low: $1

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-16Williams Trading$1129.7% upsideOpen
2026-08-12BTIGRyan Zimmerman$2359.3% upsideOpen
2025-12-01H.C. WainwrightSwayampakula Ramakanth$3589% upsideOpen
2025-10-13UBS$61278% upsideOpen
2025-08-27BarclaysMatt Miksic$3.5703.9% upsideOpen
2024-10-18Piper SandlerMatt O'Brien$61278% upsideOpen
2024-10-18BTIGRyan Zimmerman$102196.7% upsideOpen
2022-12-20Cowen & Co.Cowen Cowen$51048.4% upsideOpen
2022-05-15Piper SandlerMatt O'Brien$4818.7% upsideOpen

Humacyte (HUMA) FAQ

Humacyte (HUMA) currently reports a target price of $1.5. Use the charts on this page to explore Humacyte's target price history and peer comparisons.

Analysts' average 12-month price target for Humacyte is $1.5, about 244.5% upside from the current share price of $0.44. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $1.5, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Humacyte, and consider following HUMA for alerts when major investors trade the stock.

Humacyte is classified in the Healthcare sector. On target price, it currently shows $1.5. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HUMA with unrelated industries.